Clinical Trial Update: Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA) [Phase 3]

View source ↗

Summary

Phase 3 trial BRAVA comparing balstilimab to investigator’s choice chemotherapy in recurrent/metastatic cervical cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Balstilimab (balstilimab)

Snippet

Sponsor: Agenus Inc. | Conditions: Advanced Cancer, Metastatic Cervical Cancer | Phase 3 | Status: WITHDRAWN